MESO - メソブラスト （Mesoblast Limited） メソブラストMESOのチャート
MESOの企業情報
| symbol | MESO |
|---|---|
| 会社名 | Mesoblast Ltd （メソブラスト） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 メソブラスト（Mesoblast Limited）は骨髄や脂肪組織に由来製品の間葉系前駆細胞（MPC）技術プラットフォーム、歯髄幹細胞（DPSCs）、及び拡大造血幹細胞（HSC）を含むそのコア技術を活用した臨床開発会社である。同社の心臓血管と神経製品パイプラインはTeva Pharmaceutical Industries Ltd (Teva)との提携で開発された。同社の子会社にはMesoblast Inc.、Mesoblast International SA、Mesoblast Australia Pty Ltd及びMesoblast UK Limitedを含む。 メソブラストはオ―ストラリアバイオ医薬品企業。臨床開発段階で、骨髄と脂肪組織から派生した歯髄幹細胞と造血幹細胞を含む、間葉系幹細胞テクノロジ―プラットフォ―ムを利用した再生医療に取り組む。炎症に対する静脈内での治療、脊柱の整形、心血管や神経系疾患、目の脈管疾患などの治療を焦点に研究・開発を行う。本社はメルボルン。 |
| 本社所在地 | Level 38 55 Collins Street Melbourne Victoria 3000 AUS |
| 代表者氏名 | Silviu Itescu Silviu Itescu |
| 代表者役職名 | Chief Executive Officer Executive Director |
| 電話番号 | +61 3-9639-6036 |
| 設立年月日 | － |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 115人 |
| url | www.mesoblast.com |
| nasdaq_url | https://www.nasdaq.com/symbol/meso |
| adr_tso | 6854577 |
| EBITDA | EBITDA（百万ドル） -72.20000 |
| 終値（lastsale） | 7.3 |
| 時価総額（marketcap） | 50038412.1 |
| 時価総額 | 時価総額（百万ドル） 700.86350 |
| 売上高 | 売上高（百万ドル） 17.34100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 722.64750 |
| 当期純利益 | 当期純利益（百万ドル） -35.29000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Mesoblast limited (ADR) revenues increased from $2.4M to $17.3M. Net loss decreased 54% to $35.3M. Revenues reflect Milestone revenue increase from $500K to $13.3M Commercialization revenue increase from $1.4M to $3.6M. Lower net loss reflects Remeasurement of contingent consideratio decrease from $130K (expense) to $10.5M (income) Management and administration - Balanci decrease of 5% to $19.9M |
MESOのテクニカル分析
MESOのニュース
Why has the Mesoblast share price gained 6% so far this week? 2022/11/03 00:10:14 The Motley Fool Australia
The Mesoblast limited (ASX: MSB) share price is up 6.25% since Monday amid the company releasing its quarterly activities report.
Mesoblast reports operational and financial highlights for Q3 2022/10/31 14:27:16 Seeking Alpha
Mesoblast (MESO) reports net cash usage for operating activities in the Q3 of $14.3M; representing a reduction of $3.9M, or 22%, on the comparative quarter in FY2022, and a reduction…
Ulcerative Colitis Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - AbbVie and Boehringer Ingelheim, Eli Lilly and Company, Janssen, Mesoblast Ltd., Protagonist Therapeutics, Landos Biopharma 2022/10/13 09:37:54 OpenPR
The Ulcerative Colitis market is expected to surge due to the disease''s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ulcerative Colitis pipeline products will significantly revolutionize the Ulcerative Colitis market dynamics. DelveInsight''s "Ulcerative Colitis
Why has the Mesoblast share price marched 14% higher in 6 days? 2022/09/15 04:19:39 The Motley Fool Australia
This biotech''s shares have been charging higher recently… The post Why has the Mesoblast share price marched 14% higher in 6 days? appeared first on The Motley Fool Australia .
Piper Sandler Starts Mesoblast Limited at Overweight 2022/09/06 09:26:01 Investing.com
https://www.investing.com/news/pro/piper-sandler-starts-mesoblast-limited-at-overweight-432SI-2886348
Piper Sandler Starts Mesoblast Limited at Overweight 2022/09/06 09:26:01 Investing.com
https://www.investing.com/news/pro/piper-sandler-starts-mesoblast-limited-at-overweight-432SI-2886348
Mesoblast GAAP EPS of -$0.14, revenue of $10.21M 2022/08/31 09:16:08 Seeking Alpha
Mesoblast press release (MESO): FY GAAP EPS of -$0.14.Revenue of $10.21M (+36.9% Y/Y).BLA resubmission to FDA expected by the end of Q3 CY2022.As of June 30, 2022, cash was $60.4M,…
Mesoblast Limited (MESO) Q4 2022 Earnings Call Transcript 2022/08/31 02:28:02 Seeking Alpha
Mesoblast Limited (NASDAQ:NASDAQ:MESO) Q4 2022 Earnings Conference Call August 30, 2022, 06:30 PM ET Company Participants Silviu Itescu - CEO and MD Andrew Chaponnel - Interim CFO Eric Rose…
Mesoblast Earnings Beat, Revenue Misses In Q4 By Investing.com 2022/08/31 02:07:00 Investing.com
Mesoblast Earnings Beat, Revenue Misses In Q4
Mesoblast Limited 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:MESO) 2022/08/30 23:42:12 Seeking Alpha
The following slide deck was published by Mesoblast Limited in conjunction with their 2022 Q4 earnings call.
Mesoblast (NASDAQ:MESO) Upgraded to Buy at Zacks Investment Research 2021/11/07 05:52:44 Dakota Financial News
Zacks Investment Research upgraded shares of Mesoblast (NASDAQ:MESO) from a hold rating to a buy rating in a research note published on Wednesday morning, Zacks.com reports. The brokerage currently has $6.75 price objective on the stock. According to Zacks, Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its []
Tenaya Therapeutics (NASDAQ:TNYA) and Mesoblast (NASDAQ:MESO) Financial Contrast 2021/10/24 06:42:41 Transcript Daily
Tenaya Therapeutics (NASDAQ:TNYA) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation. Analyst Ratings This is a summary of current ratings and recommmendations for Tenaya Therapeutics and Mesoblast, []
Mesoblast Limited (NASDAQ:MESO) Receives Consensus Recommendation of Hold from Brokerages 2021/10/21 19:46:44 Dakota Financial News
Shares of Mesoblast Limited (NASDAQ:MESO) have been assigned a consensus recommendation of Hold from the seven analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year []
Regenerative Medicine Market Top Key Players, Industry Analysis And Forecast By 2027 | Athersys, Inc., Corline Biomedical AB, Mesoblast, Nuvasive, Inc. 2021/10/20 11:56:21 OpenPR
The global regenerative medicine market is anticipated to gain the market worth of US$ 178.62 billion by 2026, expanding at a CAGR of 31.5% during the forecast period 2020-2026. The major reasons that escalate the adoption of regenerative medicine are
Mesoblast Ltd - ADR Shares Approach 52-Week Low - Market Mover 2021/10/12 05:46:57 iShook Finance
Mesoblast Ltd - ADR (MESO) shares closed today at 0.4% above its 52 week low of $5.52, giving the company a market cap of $734M. The stock is currently down 33.3% year-to-date, down 53.3% over the past 12 months, and up 27.5%